Good morning :)
Place Order
Add to Watchlist

Windlas Biotech Ltd

WINDLAS

Windlas Biotech Ltd

WINDLAS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,085 cr, stock is ranked 1,131
High RiskStock is 3.60x as volatile as Nifty
997.852.38% (+23.15)
997.852.38% (+23.15)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,085 cr, stock is ranked 1,131
High RiskStock is 3.60x as volatile as Nifty
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Bad

The stock is overpriced and in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹2,085 cr, stock is ranked 1,131
High RiskStock is 3.60x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
35.004.640.55%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
52.566.720.47%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

The company provides pharmaceutical development services. It provides contract manufacturing services for pharmaceutical industrialists and also focuses on product development and manufacturing capabilities in generic products.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Industry refers to the sub-sector this company belongs to.

Higher than Industry Revenue Growth

A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 12.28%, vs industry avg of 9.03%

Increasing Market Share

Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share increased from 0.16% to 0.17%

Lower than Industry Net Income

Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -1.83%, vs industry avg of 15.28%

Loading...

Financial YearFY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024TTM
Total Revenue356.54361.07331.34436.34472.64523.05644.43676.31
Raw Materialssubtract234.55188.27224.35270.74307.56340.71386.59579.42
Power & Fuel Costsubtract7.297.288.0411.5311.0112.9016.15
Employee Costsubtract44.5442.9643.5758.3263.4170.3287.46
Selling & Administrative Expensessubtract13.8018.2916.2515.0923.5530.1535.89
Operating & Other expensessubtract12.6912.722.6544.677.98-1.2326.70
Depreciation/Amortizationsubtract17.3510.599.2912.9712.1512.3613.4416.47
Interest & Other Itemssubtract6.474.842.531.291.420.791.111.37
Taxes & Other Itemssubtract8.6512.308.455.917.4714.4118.9119.46
EPS14.1174.9117.8117.3824.6619.9627.8928.65
DPS0.000.000.000.003.504.005.504.00
Payout ratio0.000.000.000.000.140.200.200.14

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange
FY 2022

Annual report

PDF

Investor Presentation

May 12PDF
Feb 2PDF
Nov 1PDF
+2 more
FY 2023

Annual report

PDF

Investor Presentation

May 5PDF
Feb 8PDF
Nov 8PDF
Aug 4PDF
FY 2024

Annual report

PDF

Investor Presentation

Aug 8PDF
 

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Windlas Biotech Ltd35.854.640.55%
Sun Pharmaceutical Industries Ltd47.576.790.71%
Cipla Ltd30.804.740.83%
Torrent Pharmaceuticals Ltd71.4717.270.80%

Price Comparison

Compare WINDLAS with any stock or ETF
Compare WINDLAS with any stock or ETF
WINDLAS
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding62.51%8.70%1.65%1.59%25.55%

Sep 2023

Dec 2023

Mar 2024

Jun 2024

Shareholding History

AprJunSepDec '23MarJun1.24%0.80%0.80%1.35%1.18%1.59%

Mutual Funds Holding Trend

Decreased Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has decreased by 1.67%

Top 4 Mutual Funds holding Windlas Biotech Ltd




Funds (Top 4)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Plan Growth

Growth
3.6079%1.44%-0.05%22/48 (-2)
ICICI Prudential Smallcap Fund - Growth - Direct Plan

Growth
2.3102%0.52%-0.14%39/117 (-2)
UTI Healthcare Fund - Growth - Direct Plan

Growth
0.7374%1.22%-0.09%32/43 (0)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 17, 2024

Final
Final | Div/Share: ₹5.50

Dividend/Share

5.50

Ex DateEx Date

Sep 17, 2024

Cash Dividend

Ex DateEx DateSep 5, 2023

Final
Final | Div/Share: ₹4.00

Dividend/Share

4.00

Ex DateEx Date

Sep 5, 2023

Cash Dividend

Ex DateEx DateSep 9, 2022

Final
Final | Div/Share: ₹3.50

Dividend/Share

3.50

Ex DateEx Date

Sep 9, 2022

News & Opinions
Corporate
Windlas Biotech schedules AGM

Windlas Biotech announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Corporate
Windlas Biotech to hold AGM

Windlas Biotech announced that the Annual General Meeting (AGM) of the company will be held on 24 September 2024.Powered by Capital Market - Live

1 month agoCapital Market - Live
Earnings
Windlas Biotech consolidated net profit rises 11.68% in the June 2024 quarter

Net profit of Windlas Biotech rose 11.68% to Rs 13.48 crore in the quarter ended June 2024 as against Rs 12.07 crore during the previous quarter ended June 2023. Sales rose 20.97% to Rs 175.15 crore in the quarter ended June 2024 as against Rs 144.79 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales175.15144.79 21 OPM %11.9211.84 - PBDT24.5219.53 26 PBT18.3116.34 12 NP13.4812.07 12 Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Windlas Biotech to declare Quarterly Result

Windlas Biotech will hold a meeting of the Board of Directors of the Company on 13 August 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live

Windlas Biotech consolidated net profit rises 10.59% in the December 2022 quarter

1 year agoBusiness Standard

Starlit Power Systems Ltd leads losers in ‘B’ group

1 year agoBusiness Standard

Windlas Biotech posts single-digit growth numbers in Q1FY23; stock slips ~2%

2 years agoIndia Infoline

Stocks in Focus on May 13: TaMo, L&T, SBI, Eicher Motors, Windlas Biotech & More

2 years agoInvesting.com

Windlas Biotech consolidated net profit rises 150.68% in the March 2022 quarter

2 years agoBusiness Standard

Stocks in news: Reliance Industries, HCL Tech, Tata Communications, CRISIL and more

2 years agoBusiness Today